SCORE: Triamcinolone vs Standard Care for Macular Edema in RVO

Phase 3, randomised, single-blind trial of triamcinolone acetonide in macular edema (3 arms), sponsored by National Eye Institute. Primary endpoint: Proportion of participants with improvement by 15 or more letters from baseline in best-corrected ETDRS visual acuity score at 12 months. Started Mar 2005; status: completed.